MedTrace Logo

Effects of BKR-017 on Insulin Resistance in Type 2 Diabetes Patients

NCT04279444 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2020-12-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of BKR-017 on insulin resistance in type 2 diabetes (T2D) subjects during 28 days of active test product administration.

Conditions

Interventions

DIETARY_SUPPLEMENT

BKR-017

BioKier, Inc. is developing colon-targeted, oral formulations of natural gut hormone secretagogues as non-prescription medical foods or supplements for nutritional use for improvement of insulin sensitivity.

Sponsors & Collaborators

  • BioKier Inc.

    lead INDUSTRY

Principal Investigators

  • George Szewczyk, PhD · BioKier Inc.

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-16
Primary Completion
2020-11-10
Completion
2020-11-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04279444 on ClinicalTrials.gov